Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Servier licenses a diabetes drug
Swiss chemical maker will work with Germany's Max Planck Institute
by Alexander H. Tullo
October 30, 2006
| A version of this story appeared in
Volume 84, Issue 44
French drugmaker Servier has licensed the rights to develop ALS 2-0426, Alantos Pharmaceuticals' small-molecule inhibitor of dipeptidyl peptidase IV, outside the U.S. Servier will pay roughly $75 million in upfront and milestone payments and has also agreed to fund development costs for the drug through Phase II trials. ALS 2-0426 is currently in Phase I studies to treat type 2 diabetes. Under the deal, Alantos retains all U.S. rights to the drug.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter